PLRX — PLIANT THERAPEUTICS, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-06-03.
Performance
Technicals
Others in Healthcare
Measured signals that fired on PLRX
| date | signal | measured base rate |
|---|---|---|
| 2026-07-02 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-06-09 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-01-20 | Coulie Bernard President and CEO | Open-market sale 10b5-1 plan | 89.4K | 1.28 | 114.4K |
| 2026-01-20 | Cummings Keith Lamont Chief Financial Officer | Open-market sale 10b5-1 plan | 24.0K | 1.28 | 30.7K |
| 2026-01-20 | Cheung Lily Chief Human Resource Officer | Open-market sale 10b5-1 plan | 7.5K | 1.28 | 9.6K |
| 2026-01-20 | Kuo Minnie Chief Operating Officer | Open-market sale 10b5-1 plan | 6.9K | 1.28 | 8.9K |
| 2025-01-23 | Lefebvre Eric Chief Medical Officer | Grant or award | 45.6K | 0.00 | 0 |
| 2025-01-23 | Coulie Bernard President and CEO | Grant or award | 162.5K | 0.00 | 0 |
| 2025-01-23 | Cummings Keith Lamont Chief Financial Officer | Grant or award | 56.6K | 0.00 | 0 |
| 2025-01-23 | Ouimette Mike General Counsel & Corp. Sec'y | Grant or award | 35.0K | 0.00 | 0 |
| 2025-01-23 | Hull Hans Chief Business Officer | Grant or award | 40.1K | 0.00 | 0 |
| 2025-01-23 | Cheung Lily Chief Human Resource Officer | Grant or award | 25.9K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 7.7M | 6.1M |
| CITADEL ADVISORS LLC | 4.1M | 3.2M |
| Blue Owl Capital Holdings LP | 3.7M | 3.0M |
| ADAR1 Capital Management, LLC | 3.3M | 2.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | 2.3M |
| TWO SIGMA INVESTMENTS, LP | 2.8M | 2.3M |
| Monaco Asset Management SAM | 2.4M | 1.9M |
| RENAISSANCE TECHNOLOGIES LLC | 2.3M | 1.9M |
| Prosight Management, LP | 2.1M | 1.7M |
| Woodline Partners LP | 2.1M | 1.7M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 8-K | 2026-08-11 | 2026-08-11 | on EDGAR ↗ |
| 10-Q | 2026-08-11 | 2026-06-30 | on EDGAR ↗ |
| 3 | 2026-07-13 | 2026-07-09 | on EDGAR ↗ |
| 4 | 2026-07-13 | 2026-07-09 | on EDGAR ↗ |
| 3 | 2026-07-13 | 2026-07-09 | on EDGAR ↗ |
| 4 | 2026-07-13 | 2026-07-09 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Pliant Therapeutics, Inc. (PLRX) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about PLRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →